These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 27638480)

  • 1. Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.
    Späth PJ; Schneider C; von Gunten S
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):215-231. PubMed ID: 27638480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs.
    von Gunten S; Schneider C; Imamovic L; Gorochov G
    Front Immunol; 2023; 14():1166821. PubMed ID: 37063852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
    Berger M
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo
    Duellberg C; Hannappel A; Kistner S; Maneg O
    Drugs R D; 2023 Sep; 23(3):245-255. PubMed ID: 37466834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IVIG in autoimmune disease - Potential next generation biologics.
    Zuercher AW; Spirig R; Baz Morelli A; Käsermann F
    Autoimmun Rev; 2016 Aug; 15(8):781-5. PubMed ID: 27019051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyclonal IgM and IgA block in vitro complement deposition mediated by anti-ganglioside antibodies in autoimmune neuropathies.
    Sudo M; Miyaji K; Späth PJ; Morita-Matsumoto K; Yamaguchi Y; Yuki N
    Int Immunopharmacol; 2016 Nov; 40():11-15. PubMed ID: 27567246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum or breast milk immunoglobulins mask the self-reactivity of human natural IgG antibodies.
    Djoumerska-Alexieva I; Manoylov I; Dimitrov JD; Tchorbanov A
    APMIS; 2014 Apr; 122(4):329-40. PubMed ID: 23937153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the use of immunoglobulin in human disease: A review of evidence.
    Perez EE; Orange JS; Bonilla F; Chinen J; Chinn IK; Dorsey M; El-Gamal Y; Harville TO; Hossny E; Mazer B; Nelson R; Secord E; Jordan SC; Stiehm ER; Vo AA; Ballow M
    J Allergy Clin Immunol; 2017 Mar; 139(3S):S1-S46. PubMed ID: 28041678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indications and mechanisms of action of the intravenous immunoglobulines in the systemic autoimmune and inflammatory pathologies].
    Mouthon L; Bussone G; Kaveri S
    Rev Med Interne; 2009 Dec; 30(12 Suppl):H14-20. PubMed ID: 19995651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
    Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
    Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous and subcutaneous immunoglobulin G replacement therapy.
    Bonilla FA
    Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients.
    Lamari F; Karamanos NK; Papadopoulou-Alataki E; Kanakoudi-Tsakalidou F; Dimitracopoulos G; Anastassiou ED
    J Pharm Biomed Anal; 2000 Jul; 22(6):1029-36. PubMed ID: 10857572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.
    von Gunten S
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):151-2. PubMed ID: 25546801
    [No Abstract]   [Full Text] [Related]  

  • 15. [Preparation of immunoglobulins G,A,M (IgGAM) for therapeutic use. Conditions for enrichment in IgA or in IgM].
    Audran R; Pejaudier L; Steinbuch M
    Rev Fr Transfus Immunohematol; 1975 Jun; 18(2):119-35. PubMed ID: 1228846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.
    Bonagura VR
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S90-4. PubMed ID: 23271459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).
    Gardulf A
    Immunotherapy; 2016 May; 8(5):633-47. PubMed ID: 27020964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravenous immunoglobulin therapy].
    Mouthon L
    Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7(th) International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):139-40. PubMed ID: 25546796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation.
    Rieben R; Roos A; Muizert Y; Tinguely C; Gerritsen AF; Daha MR
    Blood; 1999 Feb; 93(3):942-51. PubMed ID: 9920844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.